Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Clazakizumab reduces hs-CRP in diabetes patients
Última actualización 6 de julio de 2026
Key finding
Predicted that all doses would result in the majority (≥ 80%) of subjects experiencing at least an 80% decrease in baseline hs-CRP.
This study evaluated the impact of Clazakizumab on high-sensitivity C-reactive protein (hs-CRP) levels in patients with cardiovascular disease and diabetes, finding significant decreases in hs-CRP levels with treatment.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the impact of Clazakizumab on high-sensitivity C-reactive protein (hs-CRP) levels in patients with cardiovascular disease and diabetes, finding significant decreases in hs-CRP levels with treatment.
Clinical relevance
Reducing hs-CRP levels is clinically significant as it may lower the risk of cardiovascular events in patients with diabetes and cardiovascular disease. This study suggests that Clazakizumab could be an effective treatment option to manage inflammation in these high-risk populations.
Keep in mind
Effectiveness data were unclear for some outcomes. The study's population may not be generalizable to all patients with cardiovascular disease. Limited information on long-term effects of Clazakizumab.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Venkateswari YM, Thomas K, Laura ES, et al. Impact of Clazakizumab on High-Sensitivity C-Reactive Protein in Patients with Cardiovascular Disease and Diabetes. Clinical and Translational Science. 2025;18(11):e70381. doi:10.1111/cts.70381
Efectos Principales
Clazakizumab resulted in an 80% decrease in baseline hs-CRP levels in the majority of subjects.
The proportion of subjects with hs-CRP < 2 mg/L was predicted to be 82.6% in the highest dose group.
No significant change in hs-CRP levels was observed in the placebo group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Clazakizumab and C-reactive protein, Proportion of subjects with hs-CRP < 2 mg/L.
This study contributes evidence to
Primary intervention
Clazakizumab
Primary outcomes
- C-reactive protein
- Proportion of subjects with hs-CRP < 2 mg/L
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
2
Evidence pairs
2
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 55
1
Related topics
2
Evidence pairs
32
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 2 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Inflammatory and Vascular Markers
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Proportion of subjects with hs-CRP < 2 mg/L
Clazakizumab → Proportion of subjects with hs-CRP < 2 mg/L
Clazakizumab → Proportion of subjects with hs-CRP < 2 mg/L
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Majority of subjects on Clazakizumab experienced at least an 80% decrease in hs-CRP.
- 82.6% of subjects in the highest dose group had hs-CRP < 2 mg/L.
- No significant change in hs-CRP in the placebo group.
A quién se aplica
- Adults with cardiovascular disease.
- Patients with diabetes, particularly those at high risk for cardiovascular events.
Tener en Cuenta
- Results may not apply to populations outside the study's criteria.
- Further research is needed to confirm long-term benefits of Clazakizumab.
- Effectiveness claims are based on predicted outcomes and may require additional validation.
Entre Líneas
- Effectiveness data were unclear for some outcomes.
- The study's population may not be generalizable to all patients with cardiovascular disease.
- Limited information on long-term effects of Clazakizumab.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Clazakizumab and Inflammatory Markers, Clazakizumab and Proportion of subjects with hs-CRP < 2 mg/L.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceClazakizumab → Inflammatory Markers
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Clazakizumab Evidence Hub
All studies on Clazakizumab
1 studies
intervention_hubContributes to Clazakizumab evidence base.
Inflammatory Markers Evidence Hub
All studies measuring Inflammatory Markers
1 studies
outcome_hubMeasures Inflammatory Markers as a key outcome.
Proportion of subjects with hs-CRP < 2 mg/L Evidence Hub
All studies measuring Proportion of subjects with hs-CRP < 2 mg/L
1 studies
outcome_hubMeasures Proportion of subjects with hs-CRP < 2 mg/L as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Clazakizumab and C-reactive protein
Intervention: ClazakizumabOutcome: C-reactive protein
1 results
All studies on Clazakizumab and Proportion of subjects with hs-CRP < 2 mg/L
Intervention: ClazakizumabOutcome: Proportion of subjects with hs-CRP < 2 mg/L
1 results
All studies on Clazakizumab
Intervention: Clazakizumab
1 results
All studies measuring C-reactive protein
Outcome: C-reactive protein
1 results
All studies measuring Proportion of subjects with hs-CRP < 2 mg/L
Outcome: Proportion of subjects with hs-CRP < 2 mg/L
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Clazakizumab improve c-reactive protein?
Emerging Evidence
Clazakizumab appears to improve C-reactive protein.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-reactive protein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Clazakizumab improve proportion of subjects with hs-crp < 2 mg/l?
Emerging Evidence
Clazakizumab appears to improve Proportion of subjects with hs-CRP < 2 mg/L.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Proportion of subjects with hs-CRP < 2 mg/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
BL21 Probiotic Improves Glycemic Control in Type 2 DiabetesCurcumin may improve inflammation and glycemic control in diabetesCurcumin-Piperine May Improve Oxidative Stress in Diabetic RetinopathyElderly patient with long-standing diabetes achieved sustained insulin independence through lifestyle interventionFos Biomedical patch shows no improvement in diabetes risk factors.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.